



Pros, Cons and Perspectives of SARS-CoV-2/COVID-19 Vaccines and Vaccination

Guest Editors:

Dr. Flavia Ferrantelli

National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Dr. Chiara Chiozzini

National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Deadline for manuscript submissions:

closed (1 February 2023)

Message from the Guest Editors

The need for an effective anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) vaccine has been clear since the beginning of the global pandemic, in early 2020. Within one year from SARS-CoV-2 identification, with hundreds of ad hoc vaccine studies carried out and tens of candidate vaccines advanced to clinical testing, a few novel vaccines have been approved for emergency use in humans. This unprecedented extraordinary scientific and financial effort has thrived on freely available basic science data, leading to the successful exploitation of innovative platforms against key viral targets. Nonetheless, several questions remain open as to whether the newly approved, or other yet-to-be-identified, vaccines will be able to control the COVID-19 pandemic and for how long, and whether vaccine safety will be acceptable in the long run.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com